Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares rose Monday after the company announced positive Ganaxolone data in women with postpartum depression.
The Radnor, Pa.-based Marinus, a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.
Marinus Chief Medical Officer Lorianne Masuoka, said, "Ganaxolone IV’s safety profile including ability to deliver even the highest dose at the start of infusion in these patients makes it an attractive drug candidate for this underserved patient population.
"The results from this Phase 2 safety and pharmacokinetic dose-optimization study are instrumental to future studies that incorporate our IV and provide insight to further optimize our oral dose regimen."
Ganaxolone was safe and well-tolerated in all dose groups. Consistent with previous ganaxolone studies, the most common reported adverse events were sedation and dizziness.
There were no serious adverse events reported, no discontinuations due to a treatment related adverse event and, consistent with prior studies, there were no reports of syncope or loss of consciousness.
Shares acquired 20 cents, or 3.9%, to $5.37
